A Study of RC118 in Patients With Locally Advanced Unresectable or Metastatic Malignant Solid Tumors

Advanced Solid Tumor Clinical Trial

Official title:

An Open, Multi-center Phase I/IIa Clinical Study of RC118 for Injection in Patients With Locally Advanced Unresectable or Metastatic Malignant Solid Tumors With Positive Expression of Claudin 18.2

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05205850
• Other study ID #: RC118-C001
• Status: Recruiting
• Phase: Phase 1/Phase 2
• Start date: March 3, 2022
• Est. completion date: December 1, 2025

Study information

• Verified date: December 2023
• Source: RemeGen Co., Ltd.
• Contact: Jianming Fang, ph.D
• Phone: +8610-58075763
• Email: jianmingfang[@]hotmail.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

In Phase I, This study will explore the tolerability and safety of RC118 in patients with locally advanced unresectable or metastatic malignant solid tumors with positive Claudin 18.2 expression, and determine the maximum tolerated dose (MTD) and the recommended dose in phase II clinical trials (RP2D); In Phase IIa, to explore the clinical effectiveness and safety of long-term use of RC118 at RP2D doses for patients with different tumor types。

Description:

this study is an open, single arm, multi-center Phase I /IIa clinical study. In the phase I, patients with locally advanced unresectable or metastatic malignant solid tumors (gastric cancer, esophageal cancer, gastroesophageal junction cancer, pancreatic cancer, ovarian cancer, cholangiocarcinoma, etc.) that are positive for Claudin 18.2(positive membrane staining observed in any tumor cells) will be included. in Phase I dose escalation phase, 7 dose groups will be preset：0.25 mg/kg、0.5 mg/kg、1.0 mg/kg、1.5 mg/kg、2.0 mg/kg、2.5 mg/kg、3.0mg/kg; In phase I dose confirmation phase, it is initially considered to set up 1~2 dose groups according to the dose-escalation phase MTD/MAD, with 3~6 subjects in each group. In the phase IIa cohort expansion phase, with reference to the results of the phase I study, subjects were grouped according to different tumor types, there are 30 subjects in each group, initially considering the inclusion of Claudin 18.2 positive(a clear cut-off value will be defined based on the results of Phase I) locally advanced unresectable or metastatic gastric cancer, esophageal cancer, gastroesophageal junction cancer, and pancreatic cancer patients.(The specific tumor types and groups will be further adjusted based on the results of the phase I study).

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 135
• Est. completion date: December 1, 2025
• Est. primary completion date: September 30, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

1. Volunteer to participate in this study and sign written informed consent

2. 18 years old = age = 75 years old, no gender limit

3. ECOG physical status score is 0 or 1 point

4. The expected survival time exceeds 12 weeks

5. Standard treatment is ineffective (disease progression or no remission after treatment), patients who cannot tolerate standard treatment, locally advanced unresectable or metastatic malignant solid tumors

6. The subject agrees to provide freshly collected tumor tissue specimens or collected and preserved tumor tissue specimens within 2 years during the screening period for CLDN 18.2 testing, and must meet the following criteria: A.Phase I dose escalation stage/dose confirmation stage: patients with gastric cancer, esophageal cancer, gastroesophageal junction cancer, pancreatic cancer, ovarian cancer, and cholangiocarcinoma with positive Claudin 18.2 expression (membrane staining is observed in any tumor cells); B.Phase IIa Dose Expansion phase: (positive membrane staining observed in any tumour cell) patients with gastric/gastro-oesophageal adenocarcinoma, pancreatic cancer; C. Phase IIa dose-optimisation phase: patients with gastric/gastro-oesophageal adenocarcinoma with Claudin 18.2-positive (positive membrane staining observed in any tumour cell)

7. According to the RECIST v1.1 standard, based on imaging examination (CT/MRI), there is at least one measurable or evaluable target lesion

8. Sufficient bone marrow, liver, and kidney functions (subject to the normal value of the clinical trial center): absolute neutrophil count (ANC) = 1.5×109/L, platelet = 100×109/L, hemoglobin = 90 g/ L, serum total bilirubin = 1.5 times the upper limit of normal (ULN), ALT, AST or ALP = 3 times ULN without liver metastasis; ALT, AST or ALP = 5 times ULN with liver metastasis, serum creatinine = 1.5 Times ULN, International Normalized Ratio (INR) = 1.5 times ULN, APTT = 1.5 times ULN

9. Male or female subjects with fertility must agree to take effective contraceptive measures during the study period and within 6 months after the end of the last medication, such as double-barrier contraceptive methods, condoms, oral or injectable contraceptives, intrauterine

Exclusion Criteria:

1. Women who are pregnant or breastfeeding, or women whose blood pregnancy test results are positive during the screening period (female subjects who are infertile do not need to undergo a pregnancy test, such as hysterectomy and/or bilateral ovaries in the past Women with resection or amenorrhea =12 months)

2. Subjects with positive test results for hepatitis B surface antigen (HBsAg), hepatitis C antibody (HCV-Ab), and human immunodeficiency virus antibody (HIV-Ab) during the screening period

3. Subjects with a prior history of other acquired, congenital immunodeficiency diseases; subjects who are preparing for or have previously undergone organ or bone marrow transplantation;

4. Those who have previously received targeted therapy drugs for Claudin 18.2; or participated in clinical trials of other drugs within 4 weeks before the first administration and received trial drugs

5. Have vaccinated within 4 weeks before the first dose or plan to vaccinate any vaccine during the study period

6. Allergic to known research drug ingredients or excipients

7. Combined use of vitamin K antagonist anticoagulant drugs; combined use of therapeutic doses of heparin (subjects using preventive doses of heparin can be included in the study)

8. Received anti-tumor therapy (surgery, chemotherapy, radiotherapy, biological therapy) within 4 weeks before the first administration, and received palliative radiotherapy for bone metastases within 2 weeks

9. The toxicity of previous anti-tumor treatments has not returned to the level 0 or 1 of NCI-CTCAE v5.0 (except for hair loss)

10. There are clinical symptoms of pleural fluid, ascites, and pericardial effusions require drainage (patients who do not require drainage or whose drainage is discontinued and who do not have a significant increase in effusion within 5 days may be included in the study)

11. According to the judgment of the investigator, an active infection with clinical significance

12. Combined with other diseases that seriously endanger the safety of the subject or affect the completion of the test, such as gastrointestinal bleeding (within 4 weeks before the first dose), peptic ulcer, intestinal obstruction, intestinal paralysis, interstitial pneumonia, lung Fibrosis, kidney failure, and uncontrolled diabetes

13. QTc interval during the screening period>480 ms (based on the average of 3 screening electrocardiograms); previous family or personal history of long/short QT interval syndrome; ventricular arrhythmia deemed clinically significant by the investigator Medical history, or currently receiving antiarrhythmic drug treatment, or implantation of arrhythmia defibrillation device

14. Past myocardial infarction (within 6 months before the first administration), severe or unstable angina, coronary or peripheral artery bypass grafting, New York Heart Association (NYHA) grade 3~4 heart failure, no Controlled hypertension

15. People who have had alcohol dependence or drug abuse in the past

16. Those who have received systemic steroid therapy for a long period of time (Note:

Short-term use (= 7 days) and withdrawal> 2 weeks can be selected)

17. Patients who have previously or currently suffered from uncontrolled primary or metastatic brain tumors, and the investigator believes that patients who have been stabilized or whose local treatment has ended may be considered for inclusion in the group

18. Past or current peripheral neuropathy = Grade 2

19. Past or current mental illness that is difficult to control

20. Subjects who have poor compliance and are not expected to cooperate to complete the test procedure

21. Other subjects deemed unsuitable to participate in clinical research by the investigator

22. Serious arterial/venous thrombosis or cardiovascular accident within 6 months prior to dose administration, such pulmonary embolism, cerebral infarction, cerebral hemorrhage, except for asymptomatic lacunar infarction that does not require clinical intervention;

Related Conditions & MeSH terms

• Advanced Solid Tumor
• Neoplasms

Intervention

Drug:
• RC118-ADC
RC118 for injection is a novel antibody-drug conjugate, with a Claudin 18.2-targeting antibody and a microtube inhibitor

Locations

Country	Name	City	State
China	The first affiliated hospital, zhejiang universtity school of medicine	Hangzhou	Zhejiang
China	Zhongshan Hospital Affiliated to Fudan University	Shanghai	Shanghai

Sponsors (1)

Lead Sponsor	Collaborator
RemeGen Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Dose limiting toxicity (DLT)	In the DLT evaluation window (observation period 1-28 days after the first administration), according to the NCI-CTCAE v5.0 grading standard, the investigator or the sponsor believes that toxic reaction which are reasonably related to RC118 treatment	28 days after first treatment.
Primary	The incidence and severity of adverse events (AE)	Adverse events was assessed by investigator(s) according to NCI-CTCAE v5.0	From the day of ICF sign to 28 days after the day of the last treatment
Primary	Objective response rate (ORR)	Objective Response Rate was defined as the percentage of participants with a complete response (CR) or partial response (PR)	15 months
Secondary	Disease Control Rate (DCR)	Disease Control Rate was defined as the percentage of participants with a complete response (CR) or partial response (PR) or stable disease(SD)	15 months
Secondary	Progression-free survival (PFS)	Progression-free Survival (PFS) (median) was determined using the number of months measured from the initial date of treatment to the date of documented progression, or the date of death (in the absence of progression) of participants. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions	15 months
Secondary	Duration of Remission (DOR)	Duration of response is the length of time that a tumor continues to respond to treatment without the cancer growing or spreading	15 months
Secondary	Pharmacokinetic index	Tmax ,etc.	15 months
Secondary	Immunogenicity	Anti-drug antibody (ADA) positive samples, etc.	15 months
Secondary	Overall survival(OS)	OS was defined as the time from the date of randomization to the date of death from any cause.	Up to approximately 2 years